Skip to content
Menu

Emergent BioSolutions Inc. EBS

Full chart Compare
Set alert

Price alert · EBS

All alert types
5.09 USD -0.07 (-1.26%)

As ofNov 20, 2026, 3:47 PM EST

5.03 Day range 5.13
4.36 52-week range 14.06
YTD
-58.86%
1 year
-44.00%

Fundamental scorecard

5 of 25 checks passed on EBS’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 3 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 3 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • Passed:Price to sales below its own 5-year median Price to sales 0.4 against a 5-year median of 0.5.
  • Passed:Price to book below its own 5-year median Price to book 0.8 against a 5-year median of 1.1.
  • Passed:Free cash flow yield above 4% Free cash flow of 194M is 74.3% of the market value.

Growth 0 of 5

  • Failed:Revenue grew over the last year Revenue of 649M is -17.7% on the 12 months before.
  • Failed:Revenue grew more than 5% a year over five years -14.0% a year from FY 2020 to FY 2025.
  • Failed:Earnings per share grew over the last year EPS -5.02 against 1.31 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years -30.4% a year from FY 2020 to FY 2025.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 0 of 5

  • Failed:Profitable over the last year Net income of -261M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 2 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -58.2%.
  • Failed:Net margin above its 5-year average Net margin of -40.2% against a 5-year average of -18.0%.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 2 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 558M against short-term liabilities of 122M.
  • Failed:Short-term assets cover long-term liabilities Short-term assets of 558M against long-term liabilities of 560M.
  • Failed:Net debt under 40% of equity Net debt of 331M is 105.6% of equity.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 200M is 39.4% of debt.
  • Failed:Operating profit covers interest at least 3 times Operating profit is -4.3 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What EBS owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 995M of assets

Debt, equity and cash by year

Now: 331M of debt after cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

0.23 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

4 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C-1 / 5 overall

  • DCF 1
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 1
  • P/E 1
  • P/B 4

Valuation

P/E 12.6×
P/S 0.9×
P/B 1.3×
P/FCF 4.2×
EV/EBITDA 4.3×
EV/Sales 1.4×
FCF Yield 23.7%

Profitability

Gross Margin 47.2%
Operating Margin 14.8%
Net Margin 7.1%
ROE 10.1%
ROIC 5.9%
ROA 4.0%

Growth (YoY)

Revenue -28.8%
Operating Income 201.4%
EPS (diluted) 125.8%
Free Cash Flow 338.0%

Financial Health

Current Ratio 5.0×
Quick Ratio 2.4×
Debt / Equity 1.1×
Net Debt / EBITDA 1.5×
Interest Coverage 1.9×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31